Update on rufinamide in childhood epilepsy

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 399-407

  Coppola, Giangennaro ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Dravet syndrome; Epileptic encephalopathy; Lennox gastaut syndrome; Malignant migrating partial seizures in infancy; Myoclonicastatic syndrome; Refractory childhood epilepsy; Rufinamide

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CORTICOTROPIN; ETHOSUXIMIDE; LAMOTRIGINE; PLACEBO; RUFINAMIDE; VALPROIC ACID;

ABSENCE; ADD ON THERAPY; ANOREXIA; ATONIC SEIZURE; BENIGN CHILDHOOD EPILEPSY; BRAIN DISEASE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EYE MOVEMENT DISORDER; FATIGUE; FEVER; FOCAL EPILEPSY; FOLLOW UP; GAIT DISORDER; GENE MUTATION; GENERALIZED EPILEPSY; HEADACHE; HUMAN; HYPSARRHYTHMIA; IRRITABILITY; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; MYOCLONIC ASTATIC EPILEPSY; MYOCLONUS SEIZURE; OUTCOME ASSESSMENT; RASH; REVIEW; SEDATION; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; SOMNOLENCE; TONIC SEIZURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 80053640422     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s13910     Document Type: Review

References (40)

1. McLean MHJ, Schmutz M, Pozza M, et al. The influence of rufinamide on sodium currents and action potential firing in rodent neurons[abstract]. Epilepsia. 2005;46(Suppl 8):296.
2. White HS, Schmutz M, Pozza M, Wolf H, Stables J, Kupfnerg H. The anticonvulsant profile and tolerability of rufinamide in mice and rats[abstract]. Epilepsia. 2005;46(Suppl 8):280.
3. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123-1141.
4. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia. 2009;50:1899-1909.
5. Palhagen S, Canger R, Henriksen O, van Parys JA, Riviere ME, Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res. 2001;43: 115-124.
6. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70:1950-1958.
7. Coppola G, Grosso S, Franzoni E, et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut sindrome. Eur J Neurol. 2011;18:246-251.
8. Olson HE, Loddenkemper T, Vendrame M, et al. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav. 2011;20:344-348.
9. Von Stupnagel C, Coppola G, Striano P, Muller A, Staudt M, Kluger G. First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome). Eur J Ped Neurol. 2011. [Epub ahead of press].
10. Vendrame M, Poduri A, Loddenkemper T, Kluger G, Coppola G, Kothare SV. Treatment of malignant migrating partial epilepsy of infancy with rufinamide: report of five cases. Epileptic Disord. 2011; 13:18-21.
11. Mueller A, Boor R, Coppola G, et al. Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome. Epilepsy Behav. 2011. [Epub ahead of press].
12. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on classification and terminology. Epilepsia. 2001;42:796-803.
13. Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 2009;14:491-495.
14. Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox- Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122:202-208.
15. Coppola G, Grosso S, Franzoni, et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience. Seizure. 2010;19:587-591.
16. Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol. 2010;43:155-158.
17. Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a US consensus report. Epilepsia. 2010;36:15.
18. Coppola G, Pascotto A. The medical treatment of infantile spasms. In: Guzzetta F, Dalla Bernardina B, Guerrini R, editors. Progress in Epileptic Spasms and West Syndrome: Progress in Epilepsic Disorders. Paris: John Libbey; 2007:153-173.
19. Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav. 2010;17:546-548.
20. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51:676-685.
21. Guerrini R, Parmeggiani L, Bonanni P, Kaminska A, Dulac O. Myocloni astatic epilepsy. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. 4th ed. Paris: John Libbey; 2005:115-124.
22. Doose H. Myoclonic astatic epilepsy of early childhood. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. 2nd ed. London: John Libbey; 1992:103-114.
23. Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics. 2002;33:122-132.
24. Bonanni P, Parmeggiani L, Guerrini R. Different neurophysiologic patterns of myoclonus characterize Lennox-Gastaut syndrome and myoclonic astatic epilepsy. Epilepsia. 2002;43:609-615.
25. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy: Dravet syndrome: Adv Neurol. 2005;95:71-102.
26. Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001; 68:1327-1332.
27. Nabbout R, Dulac O. Epileptic encephalopathies: a brief overview. J Clin Neurophysiol. 2003;20:393-397.
28. Mulley JC, Nelson P, Guerrero S, et al. A new molecular mechanism for severe myoclonic epilepsy of infancy: exonic deletions in SCN1A. Neurology. 2006;67:1094-1095.
29. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356: 1638-1642.
30. Coppola G, Plouin P, Chiron C, Robain O, Dulac O. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia. 1995;36:1017-1024.
31. J Jr. Report of the ILAE Classification Core Group. Epilepsia. 2006;47:1558-1568.
32. Dulac O. Malignant migrating partial seizures in infancy. In: Roger J, Bureau M, Dravet Ch, Genton P, Tassinari CA, Wolf P, editors. Epileptic Syndromes in Infancy, Childhood and Adolescence. 4th ed. Paris: John Libbey; 2005:73-76.
33. Marsh E, Melamed SE, Barron T, et al. Migrating partial seizures in infancy: expanding the phenotype of a rare seizure syndrome. Epilepsia. 2005;46:568-572.
34. Hmaimess G, Kadhim H, Nassogne MC, Bonnier C, van Rijckevorsel K. Levetiracetam in a neonate with malignant migrating partial seizures. Pediatr Neurol. 2006;34:55-59.
35. Caraballo RH, Fontana E, Darra F, et al. Migrating focal seizures in infancy: analysis of the electroclinical patterns in 17 patients. J Child Neurol. 2008;23:497-506.
36. Coppola G. Malignant migrating partial seizures in infancy: an epilepsy syndrome of unknown etiology. Epilepsia. 2009;50(Suppl 5): 49-51.
37. Coppola G, Veggiotti P, Del Giudice EM, et al. Mutational scanning of potassium, sodium and chloride ion channels in malignant migrating partial seizures in infancy. Brain Dev. 2007;28:76-79.
38. Elger CE, Stefan H, Mann A, Narurkar M, Sun Y, Perdomo C. A 24-week multicenter, randomized, double-blind, parallel-group, doseranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010;88:255-263.
39. Wheless JW, Conry J, Krauss G, Mann A, LoPresti A, Narurkar M. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol. 2009;24:1520-1525.
40. Ferrie CD, Patel A. Treatment of Lennox-Gastaut syndrome (LGS). Eur J Ped Neurol. 2009;13:493-504.